Insulet Announces ItsInsulet Wins Patent Lawsuit Against EOFlow, Federal Jury Awards $452 Million in Damages (Including $170 Million in Compensatory Damages and $282 Million in Punitive Damages).
Executive Evaluation
"We are very pleased with the jury's verdict, which confirms our commitment to protecting our technology and safeguarding our intellectual property from misappropriation and infringement. We will not only enforce our patents but also actively protect our valuable trade secrets, in which we have invested heavily to improve the lives of people with diabetes."
---Jim Hollingshead, President and CEO of InsuletThis trial by the U.S. federal court has shown medical device professionals the importance of respecting intellectual property rights, as failure to respect others' intellectual property will result in severe punishment in Europe and America.EOFlow is undoubtedly a typical example.. CurrentlyEOFloThe product has already been banned from sale in Europe and the U.S., and it also faces huge compensation, estimated...EOFlow will hereby break the deadlock. (PS:EOFlow might envy the market environment in China, as many cases have proven that intellectual property protection is quite inadequate.）ActuallyEOFlow in2011At the time of establishment, it was stillHarboring Dreams of Disruptive Technology --- Developing DisruptiveDisposable Wearable Insulin Pump。But six years laterIt is wonderful to have dreams, but the reality is cruel. Realizing that one cannot achieve a disruptive technological dream, the only option left is to resort to copying. To this end, employees from Insulet were brought in, and Flex, the contract manufacturer of Omnipod, was convinced. This led to obtaining the complete set of Omnipod technologies, resulting in the birth of the disposable wearable insulin pump EOPatch, which reeled in Brother One.Last year, Medtronic wanted to acquire EOFlow for $738 million, but fortunately, in time...DiscoveryEOFloThe product has intellectual property issues and stolen Insulet technical data.Announced at the end of last year to abandonEOFloAcquisition, timely stop-loss. Thus avoidingBillions of dollars in losses, as well as unsellable products.WithEOFlow Ban Sale toFollowing Embecta's launch of a disposable insulin patch pump, the market has returned to a monopolistic situation dominated by Insulet. It remains to be seen who can break this monopoly.Current situation, Medtronic? Or Chinese innovative enterprises?
